[1] 高超, 田秀芝, 张璐, 徐静, 汪锋, 卓志勇, 戴蕴平, 刘国世.外源褪黑素对牛卵母细胞体外成熟的影响. 中国农业科学, 2011, 44(17): 3634-3640.
GAO C, TIAN X Z, ZHANG L, XU J, WANG F, ZHUO Z Y, DAI Y P, LIU G S. Effect of exogenous melatonin (MT) in bovine oocyte in vitro maturation. Scientia Agricultura Sinica, 2011, 44(17):3634-3640. (in Chinese)
[2] BODEN G, RUIZ J, URBAIN J L, CHEN X. Evidence for a circadian rhythm of insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 1996, 271(2):E246-E252.
[3] GUARDIOLA-LEMAITRE B. Toxicology of melatonin. Journal of Biological Rhythms, 1997, 12(6):697-706.
[4] CARDINALI D P, CANO P, JIMENEZ-ORTEGA V, ESQUIFINO A I. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology, 2011, 93(3):133-142.
[5] PICINATO M C, HABER E P, CIPOLLA-NETO J, CURI R, CARVALHO C R D O, CARPINELLI A R. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. Pineal Research, 2002, 33(3): 156-160.
[6] STUMPF I, MUHLBAUER E, PESCHKE E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. Pineal Research, 2008, 45(3):318-327.
[7] STUMPF I, BAZWINSKY I, PESCHKE E. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. Pineal Research, 2009, 46(2):140-147.
[8] SHARP G W. Mechanisms of inhibition of insulin release. American Journal of Physiology-Cell Physiology, 1996, 271(6): C1781-C1799.
[9] STRAUB S G, SHARP G W G. Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins. American Journal of Physiology-Cell Physiology, 2012, 302(12): C1687-C1698.
[10] VAN CAUTER E, POLONSKY K S, SCHEEN A J. Roles of circadian rhythmicity and sleep in human glucose regulation 1. Endocrine Reviews, 1997, 18(5): 716-738.
[11] SHEA S A, HILTON M F, ORLOVA C, TIMOTHY AYERS R, MANTZOROS C S. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. The Journal of Clinical Endocrinology & Metabolism, 2005, 90(5): 2537-2544.
[12] QIAN J, SCHEER F A J L. Circadian system and glucose metabolism: Implications for physiology and disease. Trends in Endocrinology & Metabolism, 2016, 27(5): 282-293.
[13] MORRIS C J, YANG J N, SCHEER F A J L. The impact of the circadian timing system on cardiovascular and metabolic function. Progress in Brain Research, 2012, 199: 337.
[14] MORRIS C J, YANG J N, GARCIA J I, MYERSA S, BOZZIA I, WANGA W, BUXTONA O M, SHEAA S A, SCHEER F A J L. Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans. Proceedings of the National Academy of Sciences of the USA, 2015, 112(17): E2225-E2234.
[15] SCHEER F A, HILTON M F, MANTZOROS C S, SHEA S A. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proceedings of the National Academy of Sciences of the USA, 2009, 106(11):4453-4458.
[16] PESCHKE E, BÄHR I, MÜHLBAUER E. Experimental and clinical aspects of melatonin and clock genes in diabetes. Journal of Pineal Research, 2015, 59(1): 1-23.
[17] PESCHKE E. Melatonin, endocrine pancreas and diabetes. Pineal Research, 2008, 44: 26-40.
[18] SRINIVASAN V, OHTA Y, ESPINO J, PARIENTE J A, RODRIGUEZ A B, MOHAMED M, ZAKARIA R. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013, 7(1): 11-25.
[19] ZANUTO R, SIQUEIRA-FILHO M A, CAPERUTO L C, BACURAU R F, HIRATA E, PELICIARI-GARCIA R A, DO AMARAL F G, MARÇAL A C, RIBEIRO L M, CAMPOREZ J P, CARPINELLI A R, BORDIN S, CIPOLLA-NETO J, CARVALHO C R. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. Pineal Research, 2013, 55(2):156-165.
[20] BONNEFOND A, CLÉMENT N, FAWCETT K, YENGO L, VAILLANT E, GUILLAUME J L, DECHAUME A, PAYNE F, ROUSSEL R, CZERNICHOW S, HERCBERG S, HADJADJ S, BALKAU B, MARRE M, LANTIERI O, LANGENBERG C, BOUATIA-NAJI N. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nature Genetics, 2012, 44(3): 297-301.
[21] GAULTON K J, FERREIRA T, LEE Y, Raimiondo A, Mägi R. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nature Genetics, 2015, 47(12): 1415-1425.
[22] COSTES S, BOSS M, THOMAS A P, MATVEYENKO A V. Activation of melatonin signaling promotes β-cell survival and function. Molecular Endocrinology, 2015, 29(5): 682-692.
[23] RUBIO-SASTRE P, SCHEER F A, GÓMEZ-ABELLÁN P, MADRID J A, GARAULET M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep, 2014, 37(10): 1715-1719.
[24] MORRIS C J, AESCHBACH D, SCHEER F A J L. Circadian system, sleep and endocrinology. Molecular and Cellular Endocrinology, 2012, 349(1): 91-104.
[25] MÜHLBAUER E, ALBRECHT E, HOFMANN K, BAZWINSKY- WUTSCHKE I, PESCHKE E. Melatonin inhibits insulin secretion in rat insulinoma β-cells (INS-1) heterologously expressing the human melatonin receptor isoform MT2. Journal of Pineal Research, 2011, 51(3): 361-372.
[26] ZHANG Z, LI J, JIANG X, LEI Y, LEI L, DE H C, HUA Z, HONG C. GLP-1 ameliorates the proliferation activity of INS-1 cells inhibited by intermittent high glucose concentrations through the regulation of cyclins. Molecular Medicine Reports, 2014, 10(2): 683-688.
[27] TUOMI T, NAGORNY C L F, SINGH P, ET A L. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metabolism, 2016, 23: 1067-1077.
[28] HULL R L, KODAMA K, UTZSCHNEIDER K M, CARR D B, PRIGEON R L, KAHN S E. Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. Diabetologia, 2005, 48(7): 1350-1358.
[29] HELLMAN B, GRAPENGIESSER E. Glucose-induced inhibition of insulin secretion. Acta Physiologica, 2014, 210(3): 479-488.
[30] SHARMA S, SINGH H, AHMAD N, PRIYANKA M, ARCHANA T. The role of melatonin in diabetes: therapeutic implications. Archives of Endocrinology and Metabolism, 2015, 59(5): 391-397. |